Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AstraZeneca Transfers 5 Anesthetic Brands to Aspen in Japan under Global Deal
April 4, 2017
- Astellas Acquires Belgium Drug Firm Ogeda
April 4, 2017
- Takeda Consumer Healthcare Spin-Off Now Up and Running
April 4, 2017
- Pfizer Introduces Further Voluntary Recall of EpiPen 0.3 mg in Japan
April 4, 2017
- Alcon Pharma Kicks Off Operations
April 3, 2017
- Pfizer Joins Japan Biosimilar Association
April 3, 2017
- JCR’s BBB-Penetrating Hunter Syndrome Med Now in Clinical Stage
April 3, 2017
- Daiichi Sankyo Evaluating Edoxaban as Antithrombotic Therapy after Catheter Ablation
April 3, 2017
- Takeda, CiRA, RIKEN to Begin iPS-Based Research to Discover NGLY1 Deficiency Drug
April 3, 2017
- Daiichi Sankyo Files Public Knowledge-Based Application for Ovisot’s Add’l Indication
April 3, 2017
- EA Pharma Eager to Roll Out Several New Drugs in Next Couple of Years
April 3, 2017
- Orencia Filed for Juvenile Idiopathic Arthritis: BMS, Ono
March 31, 2017
- Takeda’s Dengue Vaccine Candidate Delivers Positive PII Data
March 31, 2017
- Nippon Shinyaku Gets Japan Rights to Jazz Pharma’s Defitelio and Vyxeos
March 31, 2017
- EA Pharma Earns Global Rights to Calypso’s IBD Candidate
March 31, 2017
- Oncolys Joins Hands with Osaka Univ. on Development of Next Generation Telomelysin
March 31, 2017
- Oncolys Teams up with Washington Univ. Biotech Startup
March 31, 2017
- Japan Enrollment Begins for PIII Trial for BACE inhibitor Elenbecestat: Eisai
March 30, 2017
- Tokyo Prosecutors File Appeal in Diovan Case
March 30, 2017
- Nippon Kayaku’s Remicade Biosimilar Approved for Additional Dosage for Psoriasis
March 30, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…